Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. PTC Therapeutics Inc shares valued at $89,081 were sold by Boulding Mark Elliott on May 15 ’25. At $46.18 per share, Boulding Mark Elliott sold 1,929 shares. The insider’s holdings dropped to 103,901 shares worth approximately $4.91 million following the completion of this transaction.
Also, Boulding Mark Elliott sold 883 shares, netting a total of over 40,636 in proceeds. Following the sale of shares at $46.02 each, the insider now holds 103,901 shares.
Before that, Boulding Mark Elliott had added 883 shares to its account. In a trade valued at $40,640, the Officer bought PTC Therapeutics Inc shares for $46.02 each.
As published in a research note from BofA Securities on May 09, 2025, PTC Therapeutics Inc [PTCT] has been rated up from a Neutral to a Buy and the price target has been revised to $68. Analysts at Citigroup upgraded the stock from ‘”a Sell”‘ to ‘”a Neutral”‘ outlook in a report released in early May. As of March 11, 2025, BofA Securities has increased its “an Underperform” rating to a “Neutral” for PTCT. Earlier on March 07, 2025, Scotiabank initiated its rating. Their recommendation was “a Sector perform” for PTCT stock.
Analyzing PTCT Stock Performance
During the last five days, there has been a surge of approximately 0.17%. Over the course of the year, PTC Therapeutics Inc shares have jumped approximately 4.74%. Shares of the company reached a 52-week high of $58.38 on 03/17/25 and a 52-week low of $35.95 on 05/06/25.
Support And Resistance Levels for PTC Therapeutics Inc (PTCT)
According to the 24-hour chart, there is a support level at 46.89, which, if violated, would cause prices to drop to 46.50. In the upper region, resistance lies at 47.93. The next price resistance is at 48.58. RSI (Relative Strength Index) is 52.34 on the 14-day chart, showing neutral technical sentiment.
